Meta-Analysis
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 7, 2014; 20(45): 17227-17234
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.17227
3D conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma
Li-Qun Zou, Bing-Lan Zhang, Qing Chang, Fu-Ping Zhu, Yan-Yan Li, Yu-Quan Wei, Yong-Song Guan
Li-Qun Zou, Bing-Lan Zhang, Yan-Yan Li, Yu-Quan Wei, Yong-Song Guan, Department of Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Qing Chang, Fu-Ping Zhu, Department of Hepatobiliary Surgery, The Ninth People’s Hospital of Chongqing, Chongqing 400700, China
Author contributions: Zou LQ, Zhang BL and Chang Q contributed equally to this work; Zou LQ, Zhang BL, Chang Q, Zhu FP, Li YY, Wei YQ and Guan YS designed research; Zou LQ, Zhang BL, Chang Q, Zhu FP and Li YY performed research; Zou LQ, Zhang BL, Chang Q, Wei YQ and Guan YS analyzed data; and Zou LQ, Zhang BL and Chang Q wrote the paper.
Correspondence to: Yong-Song Guan, MD, Department of Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, 37 Guoxuexiang Street, Chengdu 610041, Sichuan Province, China. yongsongguan@yahoo.com
Telephone: +86-28-85422683 Fax: +86-28-85423046
Received: February 11, 2014
Revised: June 5, 2014
Accepted: July 22, 2014
Published online: December 7, 2014
Core Tip

Core tip: Transcatheter arterial chemoembolization (TACE) is the most commonly used palliative therapy for patients with unresectable hepatocellular carcinoma (HCC), which can prolong survival with unsatisfactory long-term effects. 3D conformal radiotherapy (3D-CRT) has been utilized for HCC in a series of trials, with promising results. This meta-analysis demonstrated that TACE combined with 3D-CRT was better than TACE monotherapy for the treatment of HCC, which still needs to be confirmed by large prospectively randomized, controlled, multicenter trials.